A predictive model for intrathecal opioid dose escalation for chronic non-cancer pain

Pain Physician

Volumn 15, Issue 5, 2012, Pages 363-369

  Duarte, Rui V ^a,b   Raphael, Jon H ^a,b   Haque, Mohammad S ^c   Southall, Jane L ^b   Ashford, Robert L ^a  

^a BIRMINGHAM CITY UNIVERSITY   (United Kingdom)

^b RUSSELLS HALL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Chronic pain; Intrathecal opioid therapy; Non cancer pain; Opioid dose escalation; Predictive model

Indexed keywords

NARCOTIC ANALGESIC AGENT;

ADULT; CHRONIC PAIN; CLINICAL ARTICLE; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; FEMALE; HIGH RISK PATIENT; HUMAN; MALE; MEDICAL RECORD REVIEW; NEUROPATHIC PAIN; NOCICEPTIVE PAIN; OPIATE ADDICTION; PAIN ASSESSMENT; PREDICTION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TREATMENT DURATION;

ADULT; AGED; ANALGESICS; ANALGESICS, OPIOID; CHRONIC DISEASE; FEMALE; HUMANS; INJECTIONS, SPINAL; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PAIN; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES;

EID: 84866993584     PISSN: 15333159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Jaffe J. Drug addiction and drug abuse. In: Gilman A, Goodman L, Rall T, Murad F (eds). The Pharmacological Basis of Therapeutics. Macmillan, New York, 1985, pp 532-581.
2. Portenoy RK. Tolerance to opioid analge-sics: Clinical aspects. Cancer Surv 1994; 21:49-65.
3. Rinaldi RC, Steindler EM, Wilford BB, Goodwin D. Clarification and standardization of substance abuse terminology. JAMA 1988; 259:555-557.
4. Raphael J, Ahmedzai S, Hester J, Urch C, Barrie J, Williams J, Farquhar-Smith P, Fallon M, Hoskin P, Robb K, Bennett MI, Haines R, Johnson M, Bhaskar A, Chong S, Duarte R, Sparkes E. Cancer pain: Part 1: Pathophysiology; oncological, pharmacological, and psychological treatments: A perspective from the British Pain Society endorsed by the UK Association of Palliative Medicine and the Royal College of General Practitioners. Pain Med 2010; 11:742-764.
5. Noble M, Treadwell JR, Tregear SJ, Coates VH, Wiffen PJ, Akafomo C, Schoelles KM. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev 2010; (1):CD006605.
6. Anderson VC, Burchiel KJ. A prospective study of long-term intrathecal morphine in the management of chronic nonmalignant pain. Neurosurgery 1999; 44:289-300.
7. O'Brien C. Drug addiction and drug abuse. In: Hardman J, Limbird L (eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics. McGraw-Hill, New York, 1995, pp 557-577.
8. Sosnowski M, Yaksh TL. Differential cross-tolerance between intrathecal morphine and sufentanil in the rat. Anesthesiology 1990; 73:1141-1147.
9. Stevens CW, Yaksh TL. Studies of morphine and D-ala2-D-leu5-enkephalin (DADLE) cross-tolerance after continuous intrathecal infusion in the rat. Anesthesiology 1992; 76:596-603.
10. Berna C, Leknes S, Holmes EA, Edwards RR, Goodwin GM, Tracey I. Induction of depressed mood disrupts emotion regulation neurocircuitry and enhances pain unpleasantness. Biol Psychiatry 2010; 67:1083-1090.
11. Turk DC, Okifuji A. Psychological factors in chronic pain: Evolution and revolution. J Consult Clin Psychol 2002; 70:678-690.
12. Vlaeyen JW, Linton SJ. Fear-avoidance and its consequences in chronic musculoskeletal pain: A state of the art. Pain 2000; 85:317-332.
13. Krames ES. Intraspinal opioid therapy for chronic nonmalignant pain: Current practice and clinical guidelines. J Pain Symptom Manage 1996; 11:333-352.
14. Krames ES, Olson K. Clinical realities and economic considerations: Patient selection in intrathecal therapy. J Pain Symptom Manage 1997; 14:S3-S13.
15. Biggs SA, Duarte RV, Raphael JH, Ashford RL. Influence of a latent period in QALY analysis: Pilot study of intrathecal drug delivery systems for chronic nonmalignant pain. Br J Neurosurg 2011; 25:401-406.
16. de Lissovoy G, Brown RE, Halpern M, assenbusch SJ, Ross E. Cost-effectiveness of long-term intrathecal morphine therapy for pain associated with failed back surgery syndrome. Clin Ther 1997; 19:96-112.
17. Hassenbusch SJ, Paice JA, Patt RB, Bedder MD, Bell GK. Clinical realities and economic considerations: Economics of intrathecal therapy. J Pain Symptom Manage 1997; 14:S36-S48.
18. Atli A, Theodore BR, Turk DC, Loeser JD. Intrathecal opioid therapy for chronic nonmalignant pain: A retrospective cohort study with 3-year follow-up. Pain Med 2010; 11:1010-1016.
19. Duarte RV, Raphael JH, Sparkes E, Southall JL, LeMarchand K, Ashford RL. Long-term intrathecal drug administration for chronic nonmalignant pain. J Neurosurg Anesthesiol 2012; 24:63-70.
20. National Research Ethics Service. Differentiating audit, service evaluation and research. NRES 2006. www.nres.npsa.nhs.uk/EasySiteWeb/GatewayLink.aspx?alId=320
21. Kumar K, Kelly M, Pirlot T. Continuous intrathecal morphine treatment for chronic pain of nonmalignant etiology: Long-term benefits and efficacy. Surg Neurol 2001; 55:79-86.
22. Paice JA, Penn RD, Shott S. Intraspinal morphine for chronic pain: A retrospective, multicenter study. J Pain Symptom Manage 1996; 11:71-80.
23. Winkelmüller M, Winkelmüller W. Long-term effects of continuous intrathecal opioid treatment in chronic pain of nonmalignant etiology. J Neurosurg 1996; 85:458-467.
24. Sjöberg M, Nitescu P, Appelgren L, Curelaru I. Long-term intrathecal morphine and bupivacaine in patients with refractory cancer pain. Results from a morphine:bupivacaine dose regimen of 0.5:4.75 mg/ml. Anesthesiology 1994; 80:284-297.
25. Van Dongen RT, Crul BJ, De Bock M. Long-term intrathecal infusion of morphine and morphine/bupivacaine mixtures in the treatment of cancer pain: A retrospective analysis of 51 cases. Pain 1993; 55:119-123.
26. Veizi IE, Hayek SM, Narouze S, Pope JE, Mekhail N. Combination of intrathecal opioids with bupivacaine attenuates opioid dose escalation in chronic noncancer pain patients. Pain Med 2011; 12:1481-1489.
27. Fundytus ME. Glutamate receptors and nociception: Implications for the drug treatment of pain. CNS Drugs 2001; 15:29-58.
28. Paice JA, Winkelmüller W, Burchiel K, Racz GB, Prager JP. Clinical realities and economic considerations: Efficacy of intrathecal pain therapy. J Pain Symptom Manage 1997; 14:S14-26.
29. Zhang X, Bao L, Shi TJ, Ju G, Elde R, Hökfelt T. Down-regulation of mu-opioid receptors in rat and monkey dorsal root ganglion neurons and spinal cord after peripheral axotomy. Neuroscience 1998; 82:223-240.
30. Bernards C. Cerebrospinal fluid and spinal cord distribution of baclofen and bupivacaine during slow intrathecal infusion in pigs. Anesthesiology 2006; 105:169-178.
31. Flack SH, Anderson CM, Bernards C. Morphine distribution in the spinal cord after chronic infusion in pigs. Anesth Analg 2011; 112:460-464.
32. Bohn LM, Lefkowitz RJ, Caron MG. Differential mechanisms of morphine antinociceptive tolerance revealed in 3B2;arrestin-2 knock-out mice. J Neurosci 2002; 22:10494-10500.
33. Snyder SH. Opiate receptors in the brain. N Engl J Med 1977; 296:266-271.
34. Grady K, Raphael J. Spinal administration. In: Rice A (ed). Textbook of Clinical Pain Management: Chronic Volume. Hodder Arnold, London, 2008, pp 284-291.
35. Kumar K, Hunter G, Demeria DD. Treatment of chronic pain by using intrathecal drug therapy compared with conven pain therapies: A cost-effectiveness analysis. J Neurosurg 2002; 97:803-810.
36. Flor H, Fydrich T, Turk DC. Efficacy of multidisciplinary pain treatment centers: A meta-analytic review. Pain 1992; 49:221-230.
37. Guzmán J, Esmail R, Karjalainen K, Malmivaara A, Irvin E, Bombardier C. Multidisciplinary bio-psycho-social rehabilitation for chronic low back pain: Systematic review. BMJ 2001; 322:1511-1516.